Publications by authors named "Lambros Chrones"

Claim this Profile
H
Healthcare resource utilization patterns among patients with Parkinson's disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsychotics or versus quetiapine.
Krithika Rajagopalan, Daksha Gopal, Lambros Chrones, Dilesh Doshi, Nazia Rashid

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study.
Yasar Torres-Yaghi, Lambros Chrones, Victor Abler, Greg Brunson

BMC Neurol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Modified Functional Status Questionnaire for Assessing Patients with Parkinson's Disease Psychosis Treated with Pimavanserin: A Post Hoc Analysis.
Virgilio G H Evidente, Lambros Chrones, Ratna Revankar, Dilesh Doshi, Victor Abler

Neurol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study.
Wiesław J Cubała, Ana Berrio, Katherine Chi-Burris, Gustavo Alva, Lambros Chrones

J Alzheimers Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sedation and sleep safety of pimavanserin for Parkinsons's disease psychosis: Review and exploratory analysis of clinical study data.
Ana Berrio, Lambros Chrones, Victor Abler, Robert A Hauser

Clin Park Relat Disord· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing Longitudinal Patterns in Cognition, Mood, And Activity in Depression With 6-Week High-Frequency Wearable Assessment: Observational Study.
Francesca Cormack, Maggie McCue, Caroline Skirrow, Nathan Cashdollar, Nick Taptiklis, Lambros Chrones

JMIR Ment Health· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study.
Brandon T McDaniel, Victor Cornet, Jeanne Carroll, Lambros Chrones, Joseph Chudzik

BMC Psychiatry· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
User-Centered Design of a Digitally Enabled Care Pathway in a Large Health System: Qualitative Interview Study.
Maggie McCue, Rasha Khatib, Christopher Kabir, Chris Blair, Ben Fehnert, Lambros Chrones

JMIR Hum Factors· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Implementation of a Digitally Enabled Care Pathway to Improve Management of Depression in a Large Health Care System: Protocol for the Implementation of a Patient Care Platform.
Rasha Khatib, Maggie McCue, Chris Blair, Anit Roy, John Franco, Lambros Chrones

JMIR Res Protoc· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe survey.
Subhara Raveendran, Deepshikha Singh, Mary C Burke, Alicia H McAuliffe-Fogarty, Sagar V Parikh, Lambros Chrones

BMC Psychiatry· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mental health diagnoses and services utilization vary by wage level.
Bruce W Sherman, Debra F Lawrence, Maja Kuharic, Lambros Chrones, Sheetal Patel

Am J Manag Care· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal study to assess antidepressant treatment patterns and outcomes in individuals with depression in the general population.
Maurice M Ohayon, Maggie McCue, Andrew Krystal, Katherine J Selzler, Lambros Chrones

J Affect Disord· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study.
Gregory Mattingly, Elizabeth Brunner, Lambros Chrones, Debra F Lawrence, Kenneth Simonsen

Front Psychiatry· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An App-Based Digit Symbol Substitution Test for Assessment of Cognitive Deficits in Adults With Major Depressive Disorder: Evaluation Study.
Roger S McIntyre, Orly Lipsitz, Nelson B Rodrigues, Mehala Subramaniapillai, Flora Nasri, Lambros Chrones

JMIR Ment Health· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing primary care for patients with major depressive disorder using electronic health records of a US-based healthcare provider.
Sharon Larson, Andrei Nemoianu, Debra F Lawrence, Melissa A Troup, Michael R Gionfriddo, Lambros Chrones

J Affect Disord· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data.
Maëlys Touya, Debra F Lawrence, Anne Kangethe, Lambros Chrones, Themmi Evangelatos

BMC Psychiatry· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess Patient Support Program.
Debra F Lawrence, Janna Manjelievskaia, Lambros Chrones, Maggie McCue, Maëlys Touya

Curr Med Res Opin· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis.
Anne Kangethe, Debra F Lawrence, Maëlys Touya, Lambros Chrones, Michael Polson

BMC Health Serv Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.
Max Tsai, Lambros Chrones, Jinhui Xie, Hakop Gevorkyan, Thomas A Macek

Psychopharmacology (Berl)· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
David S Baldwin, Lambros Chrones, Ioana Florea, Rebecca Nielsen, George G Nomikos

J Psychopharmacol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Paula L Jacobsen, Atul R Mahableshwarkar, Yinzhong Chen, Lambros Chrones, Anita H Clayton

J Sex Med· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Paula L Jacobsen, Linda Harper, Lambros Chrones, Serena Chan, Atul R Mahableshwarkar

Int Clin Psychopharmacol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis